Every Man and Woman Over The Age of 50 MUST read this report from Citron Research
Short term target: $20.
3 to 5 Years: Likely Single Digit, Potential 0.
Exact Sciences (NASDAQ:EXAS) pushes a cancer test (Cologuard) to the public, inferior by its own admission, and loses money doing it. That is why this $4 billion company is mainly owned by passive investing ETFs or other healthcare baskets.
More importantly, as Citron will expose, the key metrics not disclosed by Exact Sciences are getting worse, while Medicare pricing inefficiencies end next January and investors will be left with a decaying asset with no terminal value.
This stock is a poster child for what goes wrong when Wall Street gets ahold of a health care concept with no discrimination for whether its good or bad medicine.